ReviewEXCLI journal2022
Nanocarriers for delivery of siRNA as gene silencing mediator.
Review in EXCLI journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Nanomaterials: An innovative integrative paradigm for hepatocellular carcinoma adjuvant treatment.Asian journal of pharmaceutical sciences · 2026Review
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Bioengineered exosome-mRNA hybrids: a breakthrough in targeted miRNA delivery for diabetic kidney fibrosis therapy.Frontiers in bioengineering and biotechnology · 2026Article
- Responsive nanomedicine strategies achieve pancreatic cancer precise theranostics.Bioactive materials · 2026Review
- Review
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- Research Progress on Nasal Delivery of siRNA Nanocarrier Systems for the Treatment of Neurodegenerative Diseases.Pharmaceutics · 2025Review
- Rationally designed self-assembled peptide nanofibers provoke robust humoral immunity against nervous necrosis virus.Journal of virology · 2025Article
- Advances in the regulation of macrophage polarization by the tumor microenvironment.Discover oncology · 2025Review
- RNA silencing: the future potential strategy for engineering virus resistance in plants.Physiology and molecular biology of plants : an international journal of functional plant biology · 2025Review
- Role of long non-coding RNAs and natural products in prostate cancer: insights into key signaling pathways.Functional & integrative genomics · 2025Review
- Prospects of nanotechnology and natural products for cancer and immunotherapy.Beilstein journal of nanotechnology · 2025Review
- Effect of Cyclodextrins Formulated in Liposomes and Gold and Selenium Nanoparticles on siRNA Stability in Cell Culture Medium.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Navigating Lipodystrophy: Insights from Laminopathies and Beyond.International journal of molecular sciences · 2024Review
- Naturally Occurring Phytochemicals to Target Breast Cancer Cell Signaling.Applied biochemistry and biotechnology · 2024Review
- Cationic Glucan Dendrimer Gel-Mediated Local Delivery of Anti-OC-STAMP-siRNA for Treatment of Pathogenic Bone Resorption.Gels (Basel, Switzerland) · 2024Article
- Molecularly Targeted Lanthanide Nanoparticles for Cancer Theranostic Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment.Asian journal of pharmaceutical sciences · 2023Review
- Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD).EXCLI journal · 2023Review
- Chemical Modifications Influence the Number of siRNA Molecules Adsorbed on Gold Nanoparticles and the Efficiency of Downregulation of a Target Protein.Nanomaterials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term nanocarrier refers to sub-micrometric particles of less than 100 nm, designed to transport, distribute, and release nanotechnology-based drug delivery systems. siRNA therapy is a novel strategy that has great utility for a variety of treatments, however naked siRNA delivery has not been an effective strategy, resulting in the necessary use of nanocarriers for delivery. This review aims to highlight the versatility of carriers based on smart drug delivery systems. The nanocarriers based on nanoparticles as siRNA DDS have provided a set of very attractive advantages related to improved physicochemical properties, such as high surface-to-volume ratio, versatility to package siRNA, provide a dual function to both protect extracellular barriers that lead to elimination and overcome intracellular barriers limiting cytosolic delivery, and possible chemical modifications on the nanoparticle surface to improve stability and targeting. Lipid and polymeric nanocarriers have proven to be stable, biocompatible, and effective
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.